Founded as BSI Corporation with name changed to SurModics, Inc. in 1997, in December 2011, Evonik acquired the Pharmaceitical divison of Surmodics and renamed - as Birmigham Lab - that Alabama-based component. The firm is usefuy understood as the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Management is pursuing highly differentiated medical devices designed to address unmet clinical needs and engineered to the most demanding requirements with SurModic focused on surface modification coating technologies and in vitro diagnostic (IVD) products offered to the healthcare industry. The firm's two core businesses include: Medical Devices offering surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neurovascular, urology, and other markets. The In Vitro Diagnostics segment provides component products and technologies that include protein stabilization reagents, substrates, antigens, and surface coatings for diagnostic immunoassay and molecular tests, and biomedical research applications.
